Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

@article{Onida2002PrognosticFA,
  title={Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.},
  author={Francesco Onida and Hagop M. Kantarjian and Terry L. Smith and Greg Ball and Michael J. Keating and Elihu H Estey and Armand B. Glassman and Maher Albitar and Monica I Kwari and M. Beran},
  journal={Blood},
  year={2002},
  volume={99 3},
  pages={
          840-9
        }
}
Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy characterized by wide heterogeneity of clinical presentation and course. CMML shares myelodysplastic characteristics with features of myeloproliferative disorders. No treatment has proven effective in modifying the natural course of the disease. To improve the prognostic assessment of clinical outcome, the associations of patient and disease characteristics with survival times of 213 patients with CMML was investigated… Expand
Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia
TLDR
Long-term results of allogeneic hematopoietic cell transplantation in patients with chronic myelomonocytic leukemia and determined clinical and molecular risk factors associated with outcomes revealed distinct high-risk groups with unique associations of mutations and clinical features. Expand
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems
TLDR
Analysis of clinical and prognostic aspects in 16 patients who were initially diagnosed as having a refractory anemia with excess of blasts according to FAB criteria showed some significant differences in Hb level, platelet count, percentage of immature circulating precursor, bone marrow blastosis and trilineage dysplasia, further evidence for the arbitrary nature of current classification systems. Expand
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
TLDR
A new prognostic model for overall survival, high risk and leukemia-free survival, performed better than other conventional risk models and was validated in an independent cohort of 268 CMML patients. Expand
Prognostic significance of monocytosis in patients with myeloproliferative disorders
TLDR
The diagnosis of CMML is prognostically significant and independently associated with a shorter survival and a higher risk of death than BCR/ABL-negative CML or Ph1− BCR-unknown CML, once other potentially prognostic variables have been accounted for. Expand
Current management of patients with chronic myelomonocytic leukemia
TLDR
Hypomethylating agents such as 5-azacitidine and decitabine have become the backbone of current therapy for patients with chronic myelomonocytic leukemia, but new therapeutic strategies are required to improve their outcomes. Expand
Cytogenetic risk stratification in chronic myelomonocytic leukemia
TLDR
Cytogenetic findings have a strong prognostic impact in patients with chronic myelomonocytic leukemia and were confirmed as an independent prognostic variable for overall survival on univariate and multivariate analysis. Expand
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System
TLDR
Both the original MDAPS system and a modified version derived from data of the initial cohort after extended follow-up effectively stratify both patient cohorts by survival and provide a useful risk assessment tool and additional guidance during treatment decisions. Expand
Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current Practice
TLDR
A consensus prognostic scoring system and specific response criteria are now required to facilitate the evaluation of new therapeutic strategies in clinical trials specifically dedicated to this disease. Expand
Current management of patients with chronic myelomonocytic leukemia
TLDR
The incorporation of somatic mutations to prognostic scoring systems has improved the prediction of patients’ outcomes and current treatment for CMML remains unsatisfactory. Expand
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
TLDR
Survition in young adults with CMML, although higher than in older patients, is poor and even worse in the presence of ASXL1 and SRSF2 mutations, and treatment outcome was more impressive with AHSCT than with HMA and neither was influenced by AS XL1/SRSF 2 mutations or karyotype. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases.
TLDR
Small doses of cytosine-arabinoside (ARA-C) were administered to six patients over several consecutive days and obtained a complete remission in four patients and these preliminary results must be confirmed by larger series using the diagnostic criteria proposed by the FAB cooperative group. Expand
Chronic myelomonocytic leukemia — clinicobiological characteristics: A multivariate analysis in a series of 70 cases
In a series of 70 patients diagnosed according to the FAB criteria, 42 clinical and biological disease characteristics were analyzed in order to identify significant prognostic factors by means ofExpand
Chronic myelomonocytic leukemia: natural history and prognostic determinants.
A retrospective clinical review of 41 patients with chronic myelomonocytic leukemia revealed a median age of 66 years and a male:female ratio of 2.4:1. The disease was preceded by a myelodysplasticExpand
Chronic Myelomonocytic Leukemia - Single Entity Or Heterogeneous Disorder - a Prospective Multicenter Study of 100 Patients
TLDR
The heterogeneity of this disease indicates some patients show clinical and biologic features of myeloproliferative syndromes (MDS), whereas others appear more to have myelodysplasia, shifting from refractory anemia to CMMoL, and stresses the need for a more precise definition of this entity. Expand
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
TLDR
This score was able to identify those patients with RA and RARS who, without showing an excess of marrow blasts, have an unfavorable prognosis, and a simple scoring system was devised for predicting the survival of patients with MDS. Expand
Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases.
TLDR
The study allows for the identification of subgroups with different prognoses in CMML, on the basis of a small number of hematologic parameters, particularly initial percentage of BM blasts, hemoglobin level, and leukocytosis. Expand
Chronic myelomonocytic leukemia: Clinical features, cytogenetics, and prognosis in 30 consecutive cases
TLDR
No difference in survival was found between patients who developed acute leukemia and patients who did not, and Dysplastic changes involving erythroid, granulocytic and megakaryocytic lineages were constant features in all cases. Expand
Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).
TLDR
Age, absolute monocyte counts and serum ly sozyme proved to be significant independent prognostic indicators but Cox model analyses showed serum lysozyme to be the most important factor whether taken as a continuous or discrete (two groups) variable. Expand
Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival
Summary. We have studied the clinical and laboratory features of 53 cases of chronic myelomonocytic leukaemia (CMML) defined according to the FAB criteria. A granulocyte count of < 16 x 109/l or aExpand
Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Groupe Français de Cytogénétique Hématologique.
  • Medicine
  • Cancer genetics and cytogenetics
  • 1991
TLDR
This study confirmed the cytogenetic findings previously described by this group, and its results yielded further prognostic information, which indicates the heterogeneity of this disease. Expand
...
1
2
3
4
5
...